The dataset contains the results from a randomised controlled trial assessing the effects of the sialidase inhibitor oseltamivir on the recovery of platelet counts and parameters of plasma leakage in Indonesian adult patients with acute dengue infection (TOTO trial). A total number of 70 patients with a platelet count <70 x 10^9/L and a duration of illness <7 days were randomized between oseltamivir phosphate 75mg BID or placebo for a maximum of five days. Primary outcomes were the time to platelet recovery (platelet count ≥ 100 x 109/l) or discharge from hospital and the course of measures of plasma leakage (measured by daily ultrasound, hematocrit, plasma albumin and syndecan-1 concentrations). A blood count was performed twice daily; maximum follow-up was five days. More details on the trial are given in https://doi.org/10.1186/ISRCTN35227717

results from a double blind, multicenter, randomized controlled trial.